193 related articles for article (PubMed ID: 27904045)
1. Puerarin Prevents LPS-Induced Osteoclast Formation and Bone Loss via Inhibition of Akt Activation.
Zhang Y; Yan M; Yu QF; Yang PF; Zhang HD; Sun YH; Zhang ZF; Gao YF
Biol Pharm Bull; 2016; 39(12):2028-2035. PubMed ID: 27904045
[TBL] [Abstract][Full Text] [Related]
2. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity.
Yip KH; Zheng MH; Feng HT; Steer JH; Joyce DA; Xu J
J Bone Miner Res; 2004 Nov; 19(11):1905-16. PubMed ID: 15476591
[TBL] [Abstract][Full Text] [Related]
3. Purslane suppresses osteoclast differentiation and bone resorbing activity via inhibition of Akt/GSK3β-c-Fos-NFATc1 signaling in vitro and prevents lipopolysaccharide-induced bone loss in vivo.
Kim JY; Oh HM; Kwak SC; Cheon YH; Lee MS; Rho MC; Oh J
Biol Pharm Bull; 2015; 38(1):66-74. PubMed ID: 25744460
[TBL] [Abstract][Full Text] [Related]
4. Puerarin inhibits titanium particle-induced osteolysis and RANKL-induced osteoclastogenesis via suppression of the NF-κB signaling pathway.
Tang W; Xiao L; Ge G; Zhong M; Zhu J; Qin J; Feng C; Zhang W; Bai J; Zhu X; Wei M; Geng D; Wang Z
J Cell Mol Med; 2020 Oct; 24(20):11972-11983. PubMed ID: 32896108
[TBL] [Abstract][Full Text] [Related]
5. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
6. Sinomenine down-regulates TLR4/TRAF6 expression and attenuates lipopolysaccharide-induced osteoclastogenesis and osteolysis.
He L; Duan H; Li X; Wang S; Zhang Y; Lei L; Xu J; Liu S; Li X
Eur J Pharmacol; 2016 May; 779():66-79. PubMed ID: 26965104
[TBL] [Abstract][Full Text] [Related]
7. Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-κB regulated HIF-1α and PGE(2) synthesis.
Hsieh TP; Sheu SY; Sun JS; Chen MH
Phytomedicine; 2011 Jan; 18(2-3):176-85. PubMed ID: 20554188
[TBL] [Abstract][Full Text] [Related]
8. Lipopolysaccharide (LPS) promotes osteoclast differentiation and activation by enhancing the MAPK pathway and COX-2 expression in RAW264.7 cells.
Hou GQ; Guo C; Song GH; Fang N; Fan WJ; Chen XD; Yuan L; Wang ZQ
Int J Mol Med; 2013 Aug; 32(2):503-10. PubMed ID: 23740407
[TBL] [Abstract][Full Text] [Related]
9. Lipopolysaccharide of Aggregatibacter actinomycetemcomitans up-regulates inflammatory cytokines, prostaglandin E2 synthesis and osteoclast formation in interleukin-1 receptor antagonist-deficient mice.
Mizutani H; Ishihara Y; Izawa A; Fujihara Y; Kobayashi S; Gotou H; Okabe E; Takeda H; Ozawa Y; Kamiya Y; Kamei H; Kikuchi T; Yamamoto G; Mitani A; Nishihara T; Noguchi T
J Periodontal Res; 2013 Dec; 48(6):748-56. PubMed ID: 23586622
[TBL] [Abstract][Full Text] [Related]
10. Alexidine Dihydrochloride Attenuates Osteoclast Formation and Bone Resorption and Protects Against LPS-Induced Osteolysis.
Zhu X; Gao J; Ng PY; Qin A; Steer JH; Pavlos NJ; Zheng MH; Dong Y; Cheng TS
J Bone Miner Res; 2016 Mar; 31(3):560-72. PubMed ID: 26363136
[TBL] [Abstract][Full Text] [Related]
11. IL-37 inhibits lipopolysaccharide-induced osteoclast formation and bone resorption in vivo.
Saeed J; Kitaura H; Kimura K; Ishida M; Sugisawa H; Ochi Y; Kishikawa A; Takano-Yamamoto T
Immunol Lett; 2016 Jul; 175():8-15. PubMed ID: 27154248
[TBL] [Abstract][Full Text] [Related]
12. Activation of the liver X receptor-β potently inhibits osteoclastogenesis from lipopolysaccharide-exposed bone marrow-derived macrophages.
Robertson Remen KM; Lerner UH; Gustafsson JÅ; Andersson G
J Leukoc Biol; 2013 Jan; 93(1):71-82. PubMed ID: 23099324
[TBL] [Abstract][Full Text] [Related]
13. Anti-c-Fms antibody inhibits lipopolysaccharide-induced osteoclastogenesis in vivo.
Kimura K; Kitaura H; Fujii T; Hakami ZW; Takano-Yamamoto T
FEMS Immunol Med Microbiol; 2012 Mar; 64(2):219-27. PubMed ID: 22067001
[TBL] [Abstract][Full Text] [Related]
14. Effect of BioAggregate on osteoclast differentiation and inflammatory bone resorption in vivo.
Zhang J; Zhu L; Peng B
Int Endod J; 2015 Nov; 48(11):1077-85. PubMed ID: 25358857
[TBL] [Abstract][Full Text] [Related]
15. Dual modulation of osteoclast differentiation by lipopolysaccharide.
Zou W; Bar-Shavit Z
J Bone Miner Res; 2002 Jul; 17(7):1211-8. PubMed ID: 12096834
[TBL] [Abstract][Full Text] [Related]
16. Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor.
Abu-Amer Y; Ross FP; Edwards J; Teitelbaum SL
J Clin Invest; 1997 Sep; 100(6):1557-65. PubMed ID: 9294124
[TBL] [Abstract][Full Text] [Related]
17. Lanthanum Chloride Attenuates Osteoclast Formation and Function Via the Downregulation of Rankl-Induced Nf-κb and Nfatc1 Activities.
Jiang C; Shang J; Li Z; Qin A; Ouyang Z; Qu X; Li H; Tian B; Wang W; Wu C; Wang J; Dai M
J Cell Physiol; 2016 Jan; 231(1):142-51. PubMed ID: 26060084
[TBL] [Abstract][Full Text] [Related]
18. A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression.
Kim HJ; Yoon KA; Lee MK; Kim SH; Lee IK; Kim SY
Life Sci; 2012 Nov; 91(19-20):928-34. PubMed ID: 23000100
[TBL] [Abstract][Full Text] [Related]
19. MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice.
Kim HN; Lee JH; Jin WJ; Ko S; Jung K; Ha H; Lee ZH
Eur J Pharmacol; 2012 Sep; 691(1-3):69-76. PubMed ID: 22846626
[TBL] [Abstract][Full Text] [Related]
20. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
